Literature DB >> 23541541

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Christine Katlama1, Steven G Deeks, Brigitte Autran, Javier Martinez-Picado, Jan van Lunzen, Christine Rouzioux, Michael Miller, Stefano Vella, Joern E Schmitz, Jeffrey Ahlers, Douglas D Richman, Rafick P Sekaly.   

Abstract

Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541541      PMCID: PMC3815451          DOI: 10.1016/S0140-6736(13)60104-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  106 in total

1.  Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Authors:  Frank Wolschendorf; Alexandra Duverger; Jennifer Jones; Frederic H Wagner; Jason Huff; William H Benjamin; Michael S Saag; Michael Niederweis; Olaf Kutsch
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 2.  Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis.

Authors:  Jonathan K Chan; Warner C Greene
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

3.  An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Authors:  Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

4.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

5.  The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

Authors:  Ronald Mitsuyasu; Rebecca Gelman; Deborah Weng Cherng; Alan Landay; John Fahey; Richard Reichman; Alejo Erice; R Pat Bucy; J Michael Kilby; Michael M Lederman; Carol D Hamilton; Juan Lertora; Becky L White; Pablo Tebas; Anne-Marie Duliege; Richard B Pollard
Journal:  Arch Intern Med       Date:  2007-03-26

6.  Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

Authors:  Jan van Lunzen; Tobias Glaunsinger; Ingrid Stahmer; Volker von Baehr; Christopher Baum; Andrea Schilz; Klaus Kuehlcke; Sonja Naundorf; Holger Martinius; Felix Hermann; Tsanan Giroglou; Sebastian Newrzela; Ingrid Müller; Francis Brauer; Gunda Brandenburg; Alexander Alexandrov; Dorothee von Laer
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

7.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

8.  Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.

Authors:  Takao Shishido; Frank Wolschendorf; Alexandra Duverger; Frederic Wagner; John Kappes; Jennifer Jones; Olaf Kutsch
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Authors:  Viktor von Wyl; Sara Gianella; Marek Fischer; Barbara Niederoest; Herbert Kuster; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F Günthard
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

View more
  146 in total

1.  CRISPR-mediated Activation of Latent HIV-1 Expression.

Authors:  Prajit Limsirichai; Thomas Gaj; David V Schaffer
Journal:  Mol Ther       Date:  2015-11-26       Impact factor: 11.454

2.  High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART.

Authors:  L A Ramirez; T A Arango; E Thompson; M Naji; P Tebas; J D Boyer
Journal:  J Leukoc Biol       Date:  2014-08-25       Impact factor: 4.962

3.  Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research.

Authors:  Dongzhu Ma; Cuiling Xu; Anthony R Cillo; Benjamin Policicchio; Jan Kristoff; George Haret-Richter; John W Mellors; Ivona Pandrea; Cristian Apetrei
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

4.  Screening strategies to identify host factors associated with the early and late stages of HIV-1 life cycle.

Authors:  Yi Hu; Jingxin Zhang
Journal:  Virol Sin       Date:  2013-07-26       Impact factor: 4.327

Review 5.  Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.

Authors:  Jay Rappaport; David J Volsky
Journal:  J Neurovirol       Date:  2015-05-02       Impact factor: 2.643

6.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

8.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

9.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Authors:  Steven G Deeks; Pamela M Odorizzi; Rafick-Pierre Sekaly
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

10.  Dilazep synergistically reactivates latent HIV-1 in latently infected cells.

Authors:  Hanxian Zeng; Sijie Liu; Pengfei Wang; Xiying Qu; Haiyan Ji; Xiaohui Wang; Xiaoli Zhu; Zhishuo Song; Xinyi Yang; Zhongjun Ma; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2014-08-05       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.